Shots:

• British Columbia’s Ministry of Health has reported the 3 new enoxaparin biosimilars i.e., Redesca was developed by Valero, Noromby by Juno & Inclunox by Sandoz for the prevention of blood clot disorders
• The 3 biosimilars secured public reimbursement status in British Columbia covered by PharmaCare which was the province’s public health plan while enoxaparin has been delisted. Additionally, both the original & high-potency versions of the products are available for public reimbursement
• British Columbia has adopted its policy in Nov 2019 & moved into the third phase of the program in Aug 2020 including 3 rituximab biosimilars in its options list for patients  switched from Rituxan

Ref: The Center for Biosimilars | Source: Sandoz